Clinical Trial

Feasibility Trial for a Right Ventricular Failure Platform Trial

Study acronym: CRAVE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of the CRAVE feasibility trial is to assess the feasibility of conducting a larger CRAVE platform trial by performing a randomized trial of 30 participants with pulmonary hypertension and right ventricular dysfunction, comparing empagliflozin or ranolazine plus standard of care to standard of care alone.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-08-22; most recent amendment 2025-09-16.
Status change: Not Yet Recruiting → Recruiting 2025-03-24
Trial Details
NCT Number NCT06570473
Lead Sponsor University of Alberta
Collaborators: Canadian Heart Function Alliance, Accelerating Clinical Trials Consortium, Ottawa Heart Institute Research Corporation, Team PHenomenal Hope
Conditions Pulmonary Hypertension, Right Ventricular Dysfunction, Right Heart Failure
Enrollment 30 participants
Start Date 2025-07-15
Primary Completion 2026-08 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-18